Enterome   Report issue

For profit Phase 1 Phase 2
Founded: Paris France (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2016
NCT02998190
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Enterome

Active Ingredients

Drugs in Phase 2 Trials (5)

eo2401 (3 trials)

eo2463 (1 trial)

lenalidomide (revlimid) (1 trial)

nivolumab (opdivo) (1 trial)

rituximab (rituxan) (1 trial)

Drugs in Phase 1 Trials (1)

eb8018 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adrenocortical Carcinoma (Phase 2)

Carcinoma (Phase 2)

Carotid Body Tumor (Phase 2)

Crohn Disease (Phase 1)

Glioblastoma (Phase 2)

Paraganglioma (Phase 2)

Pheochromocytoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 6